Cantor Fitzgerald Reiterates Overweight on Eli Lilly (LLY) Despite Medicare Coverage Risks, Still Sees Clear Path for Coverage Contingent on Successful Phase 3

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. SPY
3. AZN
4. FNGR
5. PLUR
6. EYPT
7. HIVE
8. GSAT
9. S
10. AGPU

Go back to Cantor Fitzgerald Reiterates Overweight on Eli Lilly (LLY) Despite Medicare Coverage Risks, Still Sees Clear Path for Coverage Contingent on Successful Phase 3

Eli Lilly's (LLY) tirzepatide Has Multi-Billion Opportunities Outside of Diabetes, Currently Undervalued - Cantor Fitzgerald

January 25, 2022 5:46 AM EST

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY) in light of the upcoming FDA decision on the company's drug tirzepatide.

The analyst quotes: "The potential approval and launch this year in Type 2 diabetes (T2D)... More